Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Zing N, Fischer T, Federico M, Chiattone C, Ferreri AJM. Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas. Crit Rev Oncol Hematol. 2021;167:103496. https://doi.org/10.1016/J.CRITREVONC.2021.103496.

Article  PubMed  Google Scholar 

Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021;137(3):374-386. https://doi.org/10.1182/blood.2020006926. These studies highlight key real-world data in Burkitt lymphoma across a large sampling of institutions, including updated estimates on CNS involvement and the importance of intensified regimens in these patients whenever possible over R-EPOCH.

Zayac AS, Evens AM, Danilov A, et al. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multi-center cohort study. Haematologica. Published online February 4, 2021. https://doi.org/10.3324/haematol.2020.270876. These studies highlight key real-world data in Burkitt lymphoma across a large sampling of institutions, including updated estimates on CNS involvement and the importance of intensified regimens in these patients whenever possible over R-EPOCH.

Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, et al. Burkitt lymphoma international prognostic index. J Clin Oncol. 2021;39(10):1129–38. https://doi.org/10.1200/JCO.20.03288.

CAS  Article  PubMed  Google Scholar 

Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis--a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk. 2015;15(8):451–7. https://doi.org/10.1016/j.clml.2015.02.026.

Article  PubMed  Google Scholar 

El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195–203. https://doi.org/10.1016/j.ejca.2016.12.029.

Article  PubMed  Google Scholar 

Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(5):1046–52. https://doi.org/10.1093/annonc/mdp432.

CAS  Article  Google Scholar 

Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ, Inwards DJ Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88(1):154-161. http://www.ncbi.nlm.nih.gov/pubmed/10618618. Accessed 29 July 2018.

Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96(7):1002–7. https://doi.org/10.3324/haematol.2011.041277.

Article  PubMed  PubMed Central  Google Scholar 

Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413-423. https://doi.org/10.1182/BLOOD.2021012888. Our own study highlights the lack of clear difference between administration routes using MTX-based prophylaxis, the uncertainties in overall efficacy with CNS prophylaxis, and the need for prospective evaluation to more definitively answer this question.

Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81. https://doi.org/10.1182/blood-2015-10-673236.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–6. https://doi.org/10.1200/JCO.2015.65.6520.

CAS  Article  PubMed  Google Scholar 

Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919–26. https://doi.org/10.1182/blood-2018-07-862862.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. https://doi.org/10.1182/blood-2003-05-1545.

CAS  Article  PubMed  Google Scholar 

El-Khouly FE, van Vuurden DG, Stroink T, et al. Effective drug delivery in diffuse intrinsic pontine glioma: a theoretical model to identify potential candidates. Front Oncol. 2017;7(OCT). https://doi.org/10.3389/FONC.2017.00254.

Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF. Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: update of the literature. Clin Pharmacokinet. 2016;55(3):297–311. https://doi.org/10.1007/S40262-015-0319-6.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Korfel A. A focus on pharmacotherapy for primary central nervous system lymphoma. Expert Rev Hematol. 2015;8(5):559–62. https://doi.org/10.1586/17474086.2015.1066672.

CAS  Article  PubMed  Google Scholar 

Slevin M, Piall E, Aherne G, Harvey V, Johnston A, Lister T. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983;1(9):546-551. https://doi.org/10.1200/JCO.1983.1.9.546.

Ferreri AJM, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist. 2011;16(3):336–41. https://doi.org/10.1634/THEONCOLOGIST.2010-0361.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466–8. https://doi.org/10.1182/blood-2002-06-1636.

CAS  Article  PubMed  Google Scholar 

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235–9. https://doi.org/10.1212/WNL.0000000000000593.

CAS  Article  PubMed  PubMed Central  Google Scholar 

El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57–68. https://doi.org/10.1016/j.ejca.2018.01.073.

Article  PubMed  PubMed Central  Google Scholar 

Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9. https://doi.org/10.1200/JCO.2013.50.4910.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10. https://doi.org/10.1182/blood-2014-10-604561.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lugtenburg PJ, de Nully Brown P, van der Holt B, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). J Clin Oncol. Published online July 30, 2020:JCO.19.03418. https://doi.org/10.1200/jco.19.03418

Fujimoto T. Pharmacokinetics of intrathecal chemotherapy and clinical problems. Gan To Kagaku Ryoho. 11(8):1536-1542.

Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745–51. https://doi.org/10.1182/blood-2012-07-440974.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Gilbar PJ, Carrington CV. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags. J Oncol Pharm Pract. 2006;12(2):113–8. https://doi.org/10.1177/1078155206070448.

Article  PubMed  Google Scholar 

Zelenetz AD. NCCN guidelines: B-cell lymphomas. Version 5.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 10 Nov 2021.

Masaki Y, Miki M, Sun Y, Nakamura T, Iwao H, Nakajima A, Kurose N, Sakai T, Jin ZX, Sawaki T, Kawanami T, Fujita Y, Tanaka M, Fukushima T, Hirose Y, Umehara H. High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma. Int J Hematol. 2011;93(6):720–6. https://doi.org/10.1007/S12185-011-0848-1.

CAS  Article  PubMed  Google Scholar 

Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian BA, Baiocchi RA, Maddocks K, Sawalha Y. Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas. Blood Adv. 2022;6(2):460–72. https://doi.org/10.1182/BLOODADVANCES.2021005999.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y. Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study. Ther Adv Hematol. 2022;13:1–16. https://doi.org/10.1177/20406207221112900.

Article  Google Scholar 

Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer. 2017;123(22):4314–24. https://doi.org/10.1002/cncr.30965.

Article  PubMed  Google Scholar 

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematol Oncol. 2017;35(4):497–503. https://doi.org/10.1002/HON.2342.

CAS  Article  PubMed  Google Scholar 

Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–27. https://doi.org/10.1016/S2352-3026(16)00036-3.

Article  PubMed 

留言 (0)

沒有登入
gif